Robeco Institutional Asset Management B.V. Sells 24,497 Shares of Jazz Pharmaceuticals PLC $JAZZ

Robeco Institutional Asset Management B.V. trimmed its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 20.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 96,418 shares of the specialty pharmaceutical company’s stock after selling 24,497 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Jazz Pharmaceuticals were worth $12,708,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Farther Finance Advisors LLC lifted its holdings in Jazz Pharmaceuticals by 754.8% in the third quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock worth $35,000 after buying an additional 234 shares during the period. Hantz Financial Services Inc. lifted its stake in shares of Jazz Pharmaceuticals by 471.4% in the 2nd quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 297 shares during the period. Geneos Wealth Management Inc. boosted its position in shares of Jazz Pharmaceuticals by 57.6% during the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 137 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Jazz Pharmaceuticals by 30.7% during the third quarter. GAMMA Investing LLC now owns 655 shares of the specialty pharmaceutical company’s stock valued at $86,000 after purchasing an additional 154 shares in the last quarter. Finally, Acadian Asset Management LLC purchased a new stake in Jazz Pharmaceuticals in the first quarter worth $90,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Trading Down 5.4%

NASDAQ:JAZZ opened at $160.25 on Friday. The stock has a market cap of $9.74 billion, a price-to-earnings ratio of -26.40, a PEG ratio of 0.79 and a beta of 0.27. The company has a quick ratio of 1.44, a current ratio of 1.65 and a debt-to-equity ratio of 1.09. The company’s 50 day moving average price is $163.37 and its 200-day moving average price is $137.06. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $182.99.

Insiders Place Their Bets

In other news, Director Bruce C. Cozadd sold 77,500 shares of the business’s stock in a transaction on Wednesday, November 26th. The stock was sold at an average price of $177.81, for a total value of $13,780,275.00. Following the completion of the transaction, the director owned 393,332 shares in the company, valued at $69,938,362.92. The trade was a 16.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Rick E. Winningham sold 5,500 shares of the stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $180.86, for a total value of $994,730.00. Following the sale, the director directly owned 8,893 shares in the company, valued at $1,608,387.98. This trade represents a 38.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 123,791 shares of company stock worth $21,991,850. 4.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have recently commented on JAZZ shares. Wells Fargo & Company boosted their target price on shares of Jazz Pharmaceuticals from $170.00 to $235.00 and gave the company an “overweight” rating in a report on Tuesday, November 18th. JPMorgan Chase & Co. dropped their price objective on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a research note on Monday, October 27th. Piper Sandler reaffirmed an “overweight” rating and set a $219.00 target price (up previously from $147.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, December 10th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a report on Monday, December 29th. Finally, UBS Group restated a “neutral” rating and issued a $188.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research note on Monday, November 24th. Thirteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $201.80.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.